Regulatory T-Cell Therapies Market

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the Treg cell therapies market in the short to mid-term and long term.

Chapter 3 provides a general overview of Treg cell therapies. In addition, it includes information on the key characteristics and function of Treg cell therapies, along with information on their mechanism of action and the challenges and future perspectives associated with Treg cell therapies. 

Chapter 4 includes detailed assessment on close to 95 Treg cell therapy candidates that are currently approved or are in different stages of development along with information on several relevant parameters, such as type of product (Tregs, interleukin 2, monoclonal antibodies, small molecules and others), phase of development (preclinical / discovery, phase I, phase I/II, phase II, phase II / III and phase III), therapeutic area (autoimmune disorders, oncological disorders, post-transplant infection, neurological disorders, metabolic disorders,  dermatological disorders, infectious diseases, and others), target indication (diabetes mellitus, graft vs host diseases, post liver transplant infection, post kidney transplant infection, amyotrophic lateral sclerosis, multiple sclerosis, myelodysplastic syndromes, atopic dermatitis and acute myeloid leukemia), source of T-cells (autologous and allogeneic), route of administration (intravenous, subcutaneous and intramuscular), dose frequency (multiple dose and single dose), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry). In addition, it presents details of the companies developing Treg cell therapies, highlighting their year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).

Chapter 5 provides detailed profiles of clinical stage Treg cell therapies (phase I/II or above); each profile features an overview of the therapy, clinical trial information, clinical trial endpoints, dosage regimen, key insights and estimated sales revenues (if available).

Chapter 6 An in-depth analysis of completed, ongoing and planned clinical studies of various Treg cell therapies, based on various relevant parameters, such as trial registration year, enrolled patient population, trial phase, trial recruitment status, study design, average time taken, target patient segment, gender of enrolled patients, type of sponsor / collaborator, leading industry players (in terms of number of registered trials conducted) and key geographical regions.

Chapter 7 features an elaborate discussion and analysis of the recent collaborations and partnerships inked between various players engaged in this domain, during the period 2015-2021 (till August). Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (R&D agreements, product development and commercialization agreements, licensing agreements, acquisitions, clinical trial agreements, manufacturing agreements and others), type of product, target therapeutic area, type of partner, key players and regional distribution of the collaborations.

Chapter 8 provides details on the various investments and grants that have been awarded to players focused on the development of Treg cell therapies. It includes a detailed analysis of the funding instances that have taken place during the period 2014 to 2021 (till August), highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain. 

Chapter 9 provides insights on a qualitative analysis highlighting five competitive forces in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.

Chapter 10 includes brief profiles of prominent players engaged in the development of Treg cell therapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio and recent developments.

Chapter 11 features an elaborate discussion on the future commercial opportunity offered by Treg cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II and above development stages taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] target indication (Crohn Disease, Bipolar Disorder, Allergic Rhinoconjunctivitis, COVID 19, Diabetes Mellitus, Systemic Lupus Erythematosus, Alzheimer Disease and Graft Vs Host Disease), [B] key players and [C] key geographies (North America, Europe and Asia Pacific)

Chapter 12 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Pascal Merchiers (Chief Scientific Officer, Oncurious).

Chapter 14 is an appendix, which provides miscellaneous charts and figures, list of figures, list of tables and list of companies and organizations.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Regulatory T-Cell Therapies
3.2. Characteristics of Treg Cell Therapies
3.3. Function of Treg Cell Therapies 
3.4 Mechanism of Action of Treg Cell Therapies 
3.5 Advantages of Treg Cell Therapies
3.6 Challenges and Future Perspectives Associated with Treg Cell Therapies

4. MARKET LANDSCAPE
4.1. Treg Cell Therapies: Overall Market Landscape
4.1.1. Analysis by Type of Product
4.1.2. Analysis by Phase of Development
4.1.3. Analysis by Therapeutic Area
4.1.4. Analysis by Phase of Development and Therapeutic Area
4.1.5. Analysis by Target Indication
4.1.6. Analysis by Source of T-Cells 
4.1.7. Analysis by Route of Administration
4.1.8. Analysis by Dose Frequency
4.1.9. Analysis by Target Patient Segment
4.1.10. Analysis by Type of Therapy
4.1.11. Analysis by Type of Developer
4.1.12. Leading Industry Players: Analysis by Number of Treg Cell Therapies
4.1.13. Leading Non-Industry Players: Analysis by Number of Treg Cell Therapies
4.2. Treg Cell Therapies: List of Developers
4.2.1. Analysis by Year of Establishment 
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Regional Landscape of Developers

5. THERAPY PROFILES
5.1. arTreg-CSB (National Institute of Allergy and Infectious Diseases / Immune Tolerance Network)
5.1.1. Company Overview
5.1.2. Therapy Overview
5.1.3. Clinical Trial Information 
5.1.4. Clinical Trial Endpoints
5.1.5. Dosage Regimen

5.2. CLBS03 (Caladrius Biosciences)
5.2.1. Company Overview
5.2.2. Therapy Overview
5.2.3. Clinical Trial Information
5.2.4. Clinical Trial Endpoints
5.2.5. Dosage Regimen
5.2.6. Key Insights
5.2.7. Estimated Sales Revenue

5.3. ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris)
5.3.1. Company Overview
5.3.2. Therapy Overview
5.3.3. Clinical Trial Information
5.3.4. Clinical Trial Endpoints
5.3.5. Dosage Regimen
5.3.6. Estimated Sales Revenue

5.4. Low Dose IL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris)
5.4.1. Company Overview
5.4.2. Therapy Overview
5.4.3. Clinical Trial Information
5.4.4. Clinical Trial Endpoints
5.4.5. Dosage Regimen
5.4.6. Key Insights

5.5. NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly)
5.5.1. Company Overview
5.5.2. Therapy Overview
5.5.3. Clinical Trial Information
5.5.4. Clinical Trial Endpoints
5.5.5. Dosage Regimen
5.5.6 Key Insights
5.5.7. Estimated Sales Revenue

5.6. RGI-2001 (REGiMMUNE)
5.6.1. Company Overview
5.6.2. Therapy Overview
5.6.3. Clinical Trial Information
5.6.4. Clinical Trial Endpoints
5.6.5. Dosage Regimen
5.6.6. Key Insights
5.6.7. Estimated Sales Revenue

5.7. rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris)
5.7.1. Company Overview
5.7.2. Therapy Overview
5.7.3. Clinical Trial Information
5.7.4. Clinical Trial Endpoints
5.7.5. Dosage Regimen
5.7.6. Estimated Sales Revenue

5.8. TR004 (Miltenyi Biotec)
5.8.1. Company Overview
5.8.2. Therapy Overview
5.8.3. Clinical Trial Information 
5.8.4. Clinical Trial Endpoints
5.8.5. Dosage Regimen
5.8.6. Estimated Sales Revenue

5.9. TX200 (Sangamo Therapeutics)
5.9.1 Company Overview
5.9.2. Therapy Overview
5.9.3. Clinical Trial Information
5.9.4. Clinical Trial Endpoints
5.9.5. Dosage Regimen
5.9.6. Key Insights

5.10. VT301 / GB301 (VT Bio / BHT Lifescience Austrailia)
5.10.1. Company Overview
5.10.2. Therapy Overview
5.10.3. Clinical Trial Information 
5.10.4. Clinical Trial Endpoints
5.10.5. Dosage Regimen

6. CLINICAL TRIAL ANALYSIS
6.1. Methodology and Parameters 
6.2. Treg Cell Therapies: Snapshot of Clinical Trials (till July 2021)
6.2.1. Analysis by Trial Registration Year and Enrolled Patient Population
6.2.2. Analysis by Trial Phase
6.2.3. Analysis by Trial Phase and Enrolled Patient Population
6.2.4. Analysis by Trial Recruitment Status
6.2.5. Analysis by Year and Trial Recruitment Status

6.2.6. Analysis by Type of Allocation
6.2.7. Analysis by Purpose of Study 
6.2.8. Analysis by Type of Masking
6.2.9 Analysis by Intervention Model
6.2.10. Analysis by Year and Trial Phase
6.2.11. Analysis by Year, Average Time Taken and Trial Phase 
6.2.12. Analysis by Target Patient Segment
6.2.13. Analysis by Gender of Enrolled Patients 
6.2.14. Analysis by Type of Sponsor(s)
6.2.15. Leading Non-Industry Players: Analysis by Number of Trials Registered
6.2.16. Leading Industry Players: Analysis by Number of Trials Registered
6.2.17. Analysis by Location of Trial
6.2.18. Analysis by Trial Status and Geography

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Treg Cell Therapies: Partnerships and Collaborations
7.2.1 Analysis by Year of Partnership
7.2.2. Analysis by Type of Partnership
7.2.3. Analysis by Year and Type of Partnership 
7.2.4. Analysis by Type of Product
7.2.5. Analysis by Year and Type of Product
7.2.6. Analysis by Therapeutic Area
7.2.7. Analysis by Type of Partner 
7.2.8. Analysis by Type of Partner and Type of Partnership
7.2.9. Leading Industry Players: Analysis by Number of Partnerships
7.2.10. Region-wise Distribution
7.2.11. Country-wise Distribution

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Treg Cell Therapies: Funding and Investment
8.2.1. Analysis by Year of Investment and Amount Invested
8.2.2. Analysis by Type of Funding
8.2.3. Analysis by Year of Investment and Type of Funding
8.2.4. Analysis by Type of Product
8.2.5. Analysis by Year of Investment and Type of Product 
8.2.6. Analysis by Type of Investor
8.2.7. Leading Investors: Analysis by Number of Funding Instances
8.2.8. Leading Players: Analysis by Number of Funding Instances
8.2.9. Analysis by Geography

9. PORTER’S FIVE FORCES ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3 Porter’s Five Forces
9.3.1. Threat of New Entrants
9.3.2. Bargaining Power of Developers
9.3.3. Bargaining Power of Customers
9.3.4. Threat of Available Substitute Therapies 
9.3.5. Rivalry Among Existing Competitors 

10. COMPANY PROFILES
10.1. Abata Therapeutics
10.1.1. Company Overview
10.1.2. Key Insights
10.1.3. Product Portfolio
10.1.4 Recent Developments and Future Outlook

10.2. Cellenkos
10.2.1. Company Overview
10.2.2. Key Insights
10.2.3. Product Portfolio
10.2.4 Recent Developments and Future Outlook

10.3. Coya Therapeutics
10.3.1. Company Overview
10.3.2. Key Insights
10.3.3. Product Portfolio
10.3.4 Recent Developments and Future Outlook

10.4. ILTOO Pharma
10.4.1. Company Overview
10.4.2. Key Insights
10.4.3. Product Portfolio
10.4.4 Recent Developments and Future Outlook

10.5. NEKTAR
10.5.1. Company Overview
10.5.2. Key Insights
10.5.3. Product Portfolio
10.5.4 Recent Developments and Future Outlook

10.6. Roche
10.6.1. Company Overview
10.6.2. Key Insights
10.6.3. Financial Information
10.6.4 Product Portfolio
10.6.5 Recent Developments and Future Outlook

10.7. Sonoma Biotherapeutics
10.7.1. Company Overview
10.7.2. Key Insights
10.7.3. Product Portfolio
10.7.4 Recent Developments and Future Outlook

10.8. TeraImmune
10.8.1. Company Overview
10.8.2. Key Insights
10.8.3. Product Portfolio
10.8.4 Recent Developments and Future Outlook

10.9. TRACT Therapeutics
10.9.1. Company Overview
10.9.2. Key Insights
10.9.3. Product Portfolio
10.9.4 Recent Developments and Future Outlook

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Treg Cell Therapies Market, 2021-2030
11.2.1. Treg Cell Therapies Market: Analysis by Type of Product
11.2.2. Treg Cell Therapies Market: Analysis by Target Indication
11.2.3. Treg Cell Therapies Market: Analysis by Key Players
11.2.4. Treg Cell Therapies Market: Analysis by Geography
11.2.5. Treg Cell Therapies: Forecast of Individual Product Sales
11.2.5.1. CLBS03 (Caladrius Biosciences): Estimated Sales Revenues
11.2.5.2. ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Estimated Sales Revenues
11.2.5.3. NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Estimated Sales Revenues
11.2.5.4. RGI-2001 (REGiMMUNE): Estimated Sales Revenues
11.2.5.5. rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Estimated Sales Revenues
11.2.5.6. TR004 (Miltenyi Biotec): Estimated Sales Revenues
11.2.5.7. VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Estimated Sales Revenues

12. CONCLUSION

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Oncurious
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Pascal Merchiers, Chief Scientific Officer

14. APPENDICES
14.1 Miscellaneous Charts and Figures
14.2 List of Figures
14.3 List of Tables
14.4 List of Companies and Organizations

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Funding and Investments
Figure 2.4 Executive Summary: Clinical Trial Analysis
Figure 2.5 Executive Summary: Market Forecast
Figure 3.1 Classification of Treg Cells
Figure 3.2 Function of Treg Cell Therapies
Figure 3.3 Mechanism of Action of Treg Cell Therapies
Figure 3.4 Advantages of Treg Cell Therapies
Figure 4.1 Treg Cell Therapies: Distribution by Type of Product
Figure 4.2 Treg Cell Therapies: Distribution by Phase of Development
Figure 4.3 Treg Cell Therapies: Distribution by Therapeutic Area
Figure 4.4 Treg Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 Treg Cell Therapies: Distribution by Target Indication
Figure 4.6 Treg Cell Therapies: Distribution by Source of T-Cell
Figure 4.7 Treg Cell Therapies: Distribution by Route of Administration
Figure 4.8 Treg Cell Therapies: Distribution by Dose Frequency
Figure 4.9 Treg Cell Therapies: Distribution by Target Patient Segment
Figure 4.10 Treg Cell Therapies: Distribution by Type of Therapy
Figure 4.11 Treg Cell Therapies Distribution by Type of Developer
Figure 4.12 Leading Industry Players: Distribution by Number of Treg Cell Therapies
Figure 4.13 Leading Non-Industry Players: Distribution by Number of Treg Cell Therapies
Figure 4.14 Treg Cell Therapy Developers: Distribution by Year of Establishment
Figure 4.15 Treg Cell Therapy Developers: Distribution by Company Size
Figure 4.16 Treg Cell Therapy Developers: Distribution by Location of Headquarters
Figure 4.17 Treg Cell Therapy Developers: Regional Landscape of Developers
Figure 5.1 CLBS03: Estimated Sales Revenue
Figure 5.2 ILT-101: Estimated Sales Revenue
Figure 5.3 NKTR-358 / LY3471851: Estimated Sales Revenue
Figure 5.4 RGI-2001: Estimated Sales Revenue
Figure 5.5 rhIL-2: Estimated Sales Revenue
Figure 5.6 TR004: Estimated Sales Revenue
Figure 5.7 VT301 / GB301: Estimated Sales Revenue
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.5 Clinical Trial Analysis: Distribution by Year and Trial Recruitment Status
Figure 6.6 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 6.7 Clinical Trial Analysis: Distribution by Purpose of Study
Figure 6.8 Clinical Trial Analysis: Distribution by Type of Masking
Figure 6.9 Clinical Trial Analysis: Distribution by Intervention Model
Figure 6.10 Clinical Trial Analysis: Distribution by Year and Trial Phase
Figure 6.11 Clinical Trial Analysis: Distribution by Year, Average Time Taken and Trial Phase
Figure 6.12 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 6.13 Clinical Trial Analysis: Distribution of Enrolled Patients by Gender
Figure 6.14 Clinical Trial Analysis: Distribution by Type of Sponsor(s)
Figure 6.15 Leading Non-Industry Players: Distribution by Number of Trials Registered
Figure 6.16 Leading Industry Players: Distribution by Number of Trials Registered
Figure 6.17 Clinical Trial Analysis: Distribution by Location of Trial
Figure 6.18 Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 7.5 Partnerships and Collaborations: Distribution by Year and Type of Product
Figure 7.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.8 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.9 Leading Industry Players: Distribution by Number of Partnerships
Figure 7.10 Partnerships and Collaborations: Distribution by Region (Continent-wise)
Figure 7.11 Partnerships and Collaborations: Distribution by Geography (Country-wise)
Figure 8.1 Funding and Investment: Distribution by Year of Investment and Amount Invested
Figure 8.2 Funding and Investment: Distribution of Instances by Type of Funding
Figure 8.3 Funding and Investment: Distribution of Amount Invested by Type of Funding
Figure 8.4 Funding and Investment: Distribution by Year of Investment and Type of Funding
Figure 8.5 Funding and Investment: Distribution by Type of Product
Figure 8.6 Funding and Investment: Distribution by Year of Investment and Type of Product
Figure 8.7 Funding and Investment: Distribution by Type of Investor
Figure 8.8 Leading Investors: Distribution by Number of Funding Instances
Figure 8.9 Leading Players: Distribution by Number of Funding Instances
Figure 8.10 Funding and Investment: Distribution of Amount Invested by Region
Figure 8.11 Funding and Investment: Distribution by Geography (Country-wise)
Figure 9.1 Porter’s Five Forces Analysis
Figure 10.1 Roche: Annual Revenues, 2017-2020 (USD Billion)
Figure 11.1 Overall Treg Cell Therapies Market, 2021-2035 (USD Million)
Figure 11.2 Treg Cell Therapies Market, 2021-2035: Distribution by Type of Product (USD Million)
Figure 11.3 Treg Cell Therapies Market, 2021-2035: Distribution by Target Indication (USD Million)
Figure 11.4 Treg Cell Therapies Market, 2021-2035: Distribution by Key Players (USD Million)
Figure 11.5 Treg Cell Therapies Market, 2021-2035: Distribution by Geography (USD Million)
Figure 11.6 CLBS03 (Caladrius Biosciences): Sales Forecast, 2021-2035 (USD Million)
Figure 11.7 ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Sales Forecast, 2021-2035 (USD Million)
Figure 11.8 NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Sales Forecast, 2021-2035 (USD Million)
Figure 11.9 RGI-2001 (REGiMMUNE): Sales Forecast, 2021-2035 (USD Million)
Figure 11.10 rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Sales Forecast, 2021-2035 (USD Million)
Figure 11.11 TR004 (Miltenyi Biotec): Sales Forecast, 2021-2035 (USD Million)
Figure 11.12 VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Sales Forecast, 2021-2035 (USD Million)
Figure 12.1 Concluding Remarks: Overall Market Landscape
Figure 12.2 Concluding Remarks: Partnerships and Collaborations
Figure 12.3 Concluding Remarks: Funding and Investments
Figure 12.4 Concluding Remarks: Clinical Trial Analysis
Figure 12.5 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Characteristics of Treg Cell Therapies
Table 4.1 List of Treg Cell Therapies
Table 4.2 List of Treg Cell Therapy Developers
Table 5.1 arTreg-CSB (National Institute of Allergy and Infectious Diseases / Immune Tolerance Network): Clinical Trial Information
Table 5.2 arTreg-CSB (National Institute of Allergy and Infectious Diseases / Immune Tolerance Network): Clinical Trial Endpoints
Table 5.3 arTreg-CSB (National Institute of Allergy and Infectious Diseases / Immune Tolerance Network): Dosage Regimen
Table 5.4 CLBS03 (Caladrius Biosciences): Clinical Trial Information
Table 5.5 CLBS03 (Caladrius Biosciences): Clinical Trial Endpoints
Table 5.6 CLBS03 (Caladrius Biosciences): Dosage Regimen
Table 5.7 CLBS03 (Caladrius Biosciences): Key Insights
Table 5.8 ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Information
Table 5.9 ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Endpoints
Table 5.10 ILT-101 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Dosage Regimen
Table 5.11 Low Dose IL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Information
Table 5.12 Low Dose IL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Endpoints
Table 5.13 Low Dose IL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Dosage Regimen
Table 5.14 Low Dose IL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Key Insights
Table 5.15 NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Clinical Trial Information
Table 5.16 NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Clinical Trial Endpoints
Table 5.17 NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Dosage Regimen
Table 5.18 NKTR-358 / LY3471851(Nektar Therapeutics / Eli Lilly): Key Insights
Table 5.19 RGI-2001 (REGiMMUNE): Clinical Trial Information
Table 5.20 RGI-2001 (REGiMMUNE): Clinical Trial Endpoints
Table 5.21 RGI-2001 (REGiMMUNE): Dosage Regimen
Table 5.22 RGI-2001 (REGiMMUNE): Key Insights
Table 5.23 rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Information
Table 5.24 rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Clinical Trial Endpoints
Table 5.25 rhIL-2 (Iltoo Pharma / Assistance Publique - Hôpitaux de Paris): Dosage Regimen
Table 5.26 TR004 (Miltenyi Biotec): Clinical Trial Information
Table 5.27 TR004 (Miltenyi Biotec): Clinical Trial Endpoints
Table 5.28 TR004 (Miltenyi Biotec): Dosage Regimen
Table 5.29 TX200 (Sangamo Therapeutics): Clinical Trial Information
Table 5.30 TX200 (Sangamo Therapeutics): Clinical Trial Endpoints
Table 5.31 TX200 (Sangamo Therapeutics): Dosage Regimen
Table 5.32 TX200 (Sangamo Therapeutics): Key Insights
Table 5.33 VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Clinical Trial Information
Table 5.34 VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Clinical Trial Endpoints
Table 5.35 VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Dosage Regimen
Table 5.36 VT301 / GB301 (VT Bio / BHT Lifescience Austrailia): Key Insights
Table 6.1 Treg Cell Therapies: Snapshot of Clinical Trials
Table 7.1 Treg Cell Therapies: Partnerships and Collaborations
Table 8.1 Treg Cell Therapies: Funding and Investment
Table 10.1 Abata Therapeutics: Product Portfolio
Table 10.2 Abata Therapeutics: Recent Developments and Future Outlook
Table 10.3 Cellenkos: Product Portfolio
Table 10.4 Cellenkos: Recent Developments and Future Outlook
Table 10.5 Coya Therapeutics: Product Portfolio
Table 10.6 Coya Therapeutics: Recent Developments and Future Outlook
Table 10.7 ILTOO Pharma: Product Portfolio
Table 10.8 ILTOO Pharma: Recent Developments and Future Outlook
Table 10.9 NEKTAR: Product Portfolio
Table 10.10 NEKTAR: Recent Developments and Future Outlook
Table 10.11 Roche: Product Portfolio
Table 10.12 Roche: Recent Developments and Future Outlook
Table 10.13 Sonoma Biotherapeutics: Product Portfolio
Table 10.14 Sonoma Biotherapeutics: Recent Developments and Future Outlook
Table 10.15 TeraImmune: Product Portfolio
Table 10.16 TeraImmune: Recent Developments and Future Outlook
Table 10.17 TRACT Therapeutics: Product Portfolio
Table 10.18 TRACT Therapeutics: Recent Developments and Future Outlook
Table 14.1 Appendices

List Of Companies

1. 8VC
2. Abata Therapeutics
3. Abingworth
4. Accelerate NY Seed Fund
5. Access Biotechnology
6. ADC Therapeutics
7. Advantech Capital
8. Advent France Biotechnology
9. Agenus
10. Ain Shams University
11. Alderaan Biotechnology
12. Alexandria Venture Investments
13. Allele Capital Partners
14. Alliancells-PuRui Biocience 
15. Ankara University
16. ARCH Venture Partners
17. Assistance Publique - Hôpitaux de Paris
18. Assiut University
19. Autoimmunity Centers of Excellence (ACE)
20. Avidity Partners
21. Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
22. Baylor College of Medicine
23. Bayside Health & Rehabilitation Center
24. BeiGene
25. Beijing Ditan Hospital
26. Beijing Tongren Hospital
27. Belgian Hematology Society
28. Benaroya Research Institute at Virginia Mason (BRI)
29. Beth Israel Deaconess Medical Center
30. BHT LIFESCIENCE AUSTRALIA
31. Bioinova
32. Boston Children's Hospital
33. Boston Immune Technologies and Therapeutics (BITT)
34. Boxer Capital
35. Bpifrance
36. Brigham and Women's Hospital
37. Bristol-Myers Squibb
38. Brugmann University Hospital
39. Cairo University
40. Caladrius Biosciences
41. California Institute for Regenerative Medicine
42. Cambridge University Hospitals NHS Foundation Trust
43. Cancer Prevention Research Institute of Texas
44. CDH Investments
45. Celgene
46. Celldex Therapeutics
47. Cellenkos
48. Center Eugene Marquis
49. Center for Cell and Gene Therapy
50. Central South University
51. Centre Hospitalier du Valais Romand
52. Centre Hospitalier Universitaire de NÄ«mes
53. Centre Hospitalier Universitaire de Nice
54. Centre Hospitalier Universitaire de Saint-Etienne
55. Centre Hospitalier Universitaire Dijon
56. Charité – Universitätsmedizin Berlin
57. Chia Tai Tianqing Pharmaceutical
58. China Life Private Equity Investment Company 
59. Chinese PLA General Hospital
60. Chulalongkorn University
61. Country Garden Venture Capital
62. Coya Therapeutics
63. CRISPR Therapeutics
64. Dana-Farber Cancer Institute
65. DCVC Bio
66. Diabetes Research Institute Foundation Canada (DRIFCan)
67. Duke University
68. Dutch Cancer Society
69. EcoR1 Capital
70. EDBI
71. Efung Capital
72. Egle Therapeutics 
73. EGP 
74. ElevateBio
75. Eli Lilly
76. Emerson Collective
77. Emory University School of Medicine
78. Entos Pharmaceuticals
79. EpiVax
80. European Commission
81. F2 Ventures
82. FairJourney Biologics
83. Fakultas Kedokteran Universitas Indonesia (FKUI)
84. Fidelity Research & Management Company
85. Flanders Innovation and Entrepreneurship
86. Fondation ARSEP
87. Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
88. Fondazione Italiana Sclerosi Multipla
89. Forge Biologics
90. Franklin Templeton Investments
91. Friedreich’s Ataxia Research Alliance (FARA)
92. FUNDACION FAMILIA ALONSO
93. Fundación Pública Andaluza para la Gestión de la (FISEVI)
94. GEMABIOTECH
95. GentiBio
96. GIC
97. Gilead Sciences
98. Greater Bay Area Investments Groups
99. Greater Paris University Hospitals
100. GTJA Investment Group
101. Guy's and St Thomas' NHS Foundation Trust
102. H. Lee Moffitt Cancer Center and Research Institute
103. Hackensack Meridian Health
104. Hanmi Pharmaceuticals
105. Hannover Medical School
106. Harbour BioMed
107. Hatteras Venture Partners
108. Hoffmann-La Roche
109. Horatio Ventures NYC.
110. Hospital de Santa Maria
111. Hospital General Universitario Gregorio Marañón
112. Hualan Genetic
113. Hudson Bay Capital
114. Hunan Xeno Life Science
115. Icahn School of Medicine at Mount Sinai
116. ILTOO Pharma
117. Immune Tolerance Network
118. Imperial College London
119. Indoor Biotechnologies
120. Incyte
121. Inria
122. Inserm
123. Institut Polyclinique de Cannes (IPOCA)
124. Institute of Hematology and Blood Diseases Hospital
125. Instituto de Medicina Molecular JoÃo Lobo Antunes
126. Instituto de Salud Carlos III
127. IONTAS 
128. Instituto Português de Oncologia de Lisboa (IPO Lisboa)
129. Instituto Portugues De Oncologia Do Porto Francisco Gentil
130. IQVIA
131. IRCCS Azienda Ospedaliero Universitaria di Bologna
132. IRCCS Ospedale San Raffaele
133. IRCCS Policlinico San Matteo
134. ITOCHU
135. Japan Asia Investment 
136. JDRF T1D Fund
137. Tianhe Stem Cell Biotechnologies
138. Jonsson Comprehensive Cancer Center
139. Jounce Therapeutics
140. JT New Century
141. Jules Bordet Institute
142. Junten Bio
143. Juntendo University
144. Juvenile Diabetes Research Foundation
145. Kaiser Foundation Hospital 
146. Kaiser Permanente 
147. King's College London
148. Kurume University
149. Kyverna Therapeutics
150. Lausanne University Hospital
151. Legend Capital
152. Liana's Dream Foundation
153. LifeForce Capital
154. Lightspeed Venture Partners
155. Lilly Asia Ventures
156. Loyola University
157. Lyell Immunopharma
158. MD Anderson Cancer Center
159. Maastricht University Medical Center
160. Mahidol University
161. Maisonneuve-Rosemont Hospital
162. MANRESANA de MICOBACTERIOLOGIA
163. Mashhad University of Medical Sciences
164. Massachusetts General Hospital Cancer Center
165. Matrix Capital Management
166. MD Anderson Cancer Center
167. Medical Research Council
168. Medical University of Graz
169. Medical University of Lodz
170. Medical University of Vienna
171. Medicxi
172. Mesoblast
173. Methodist Health System
174. MIGAL Galilee Research Institute 
175. Milky Way Ventures
176. Miltenyi Biomedicine
177. Miltenyi Biotech
178. Mission BioCapital (formerly known as BioInnovation Capital)
179. Mogrify
180. Moleculin Biotech
181. Morningside Venture Investments
182. Mount Sinai Hospital
183. MPM Capital
184. Mubadala Investment Company
185. Nanjing Medical University
186. National Cancer Institute
187. National Health Security Office (NHSO)
188. National Heart, Lung, and Blood Institute (NHLBI)
189. National Institute for Health Research
190. National Institute of Allergy and Infectious Diseases (NIAID)
191. National Institutes of Health (NIH)
192. NIH Clinical Center (CC)
193. National Multiple Sclerosis Society
194. National Natural Science Foundation of China
195. National Taiwan University Hospital
196. ND Capital
197. Nektar Therapeutics
198. New Enterprise Associates
199. New Leaf Venture Partners
200. NextWavebio
201. Nicoya Lifesciences
202. Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS)
203. Northwestern University
204. Nova Immunotherapeutics
205. Novartis Pharmaceuticals
206. Novartis Venture Fund
207. Numeric Biotech
208. NYU Langone’s Perlmutter Cancer Center
209. Octagon Capital
210. Oncurious
211. OrbiMed
212. Orbis Medical Centre
213. Orca Bio
214. Pandion Therapeutics (acquired by Merck)
215. Pierre and Marie Curie University
216. Pirogov Russian National Research Medical University
217. PLA Navy General Hospital
218. Polaris Partners
219. Prometheus Laboratories
220. Quell Therapeutics
221. RA Capital Management
222. Radboud University
223. Rapa Therapeutics
224. RAPT Therapeutics
225. Redmile Group
226. REGiMMUNE
227. Rho Federal Systems Division
228. Roche
229. Royan Institute
230. Russian Academy of Medical Sciences
231. Sage Partners
232. Samsara BioCapital
233. Sanford Burnham Prebys Medical Discovery Institute
234. Sanford health
235. Sangamo Therapeutics
236. Scale AI
237. Seattle Children’s Research Institute
238. Second Xiangya Hospital of Central South University
239. Selexis 
240. Servier
241. Seventh Framework Programme
242. Shandong University
243. Shanghai Institute of Acupuncture, Moxibustion and Meridian
244. Sheffield Institute for Translational Neuroscience
245. Sir Jules Thorn Charitable Trust
246. SK Holdings
247. Small Business Administration
248. Small Business Innovation Research (SBIR)
249. SMBC Venture Capital
250. Sonoma Biotherapeutics
251. SR One
252. St George Street Capital
253. St. George's Hospital
254. St. Jude Children's Research Hospital
255. Stanford University
256. State-Financed Health Facility “Samara Regional Medical Center Dinasty”
257. Sumitomo Mitsui Banking Corporation (SMBC)
258. Surveyor Capital
259. Syncona
260. Tabriz University of Medical Sciences
261. Takeda
262. Tanta University
263. Targazyme
264. TeraImmune
265. The Egyptian IVF-ET Center
266. The Faculty of Medicine Siriraj Hospital
267. The First Affiliated Hospital of Soochow University
268. The Invus Group
269. The Leona M. and Harry B. Helmsley Charitable Trust
270. The Methodist Hospital Research Institute
271. TRACT Therapeutics
272. TregTherapeutics
273. Tusk Therapeutics (acquired by Roche)
274. TxCell
275. University Hospital Regensburg
276. University Hospital of Bordeaux
277. University Hospital of Montpellier
278. University of Alberta
279. University of Bergen
280. University of Bologona
281. University of California, San Francisco
282. University of Cambridge
283. University of Chicago
284. University of Colorado
285. University of Erlangen-Nuremberg
286. University of Illinois Chicago
287. University of Kentucky
288. University of Liege
289. University of London
290. University of lowa College of Pharmacy
291. University of Minnesota
292. University Of Minnesota Medical School
293. University of Nottingham
294. University of Naples Federico II
295. University of Perugia
296. University of Regensburg
297. University of Texas
298. University of Texas
299. University of Washington
300. University of Zurich
301. Université Paris-Est Créteil
302. VA Office of Research and Development
303. Versant Ventures
304. Vertex Ventures
305. Vida Ventures
306. Vir Biotechnology
307. VT BIO
308. Washington University School of Medicine
309. Wellcome Trust
310. Westlake Village BioPartners
311. Xian Janssen Pharmaceutical
312. Yale University
313. Zhejiang University
314. Zheshang Venture Capital
315. Zhongyuan Union Stem Cell Bioengineering

Source 1: www.who.int/news-room/fact-sheets/detail/cancer
Source 2: www.frontiersin.org/articles/10.3389/fimmu.2019.00043/full